Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18

Fecha de inicio: 1 de septiembre de 2003

INCLUSION: * Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis: * AFP \> 200 mg/dL; * A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or * A tumor mass confirmed by arteriography. * Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging. EXCLUSION: * Pediatric patients under the age of 18 will be excluded from consideration from this study. * Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible. * Pregnant and breastfeeding patients. * Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)